U.S. Markets closed

Tesaro, Inc. (TSRO)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
113.86+4.81 (+4.41%)
At close: 4:00PM EDT
People also watch
Full screen
Previous Close109.05
Bid92.00 x 200
Ask166.00 x 100
Day's Range107.50 - 115.72
52 Week Range83.26 - 192.94
Avg. Volume1,280,546
Market Cap6.13B
PE Ratio (TTM)-13.36
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.com12 hours ago

    Tesaro: Losing Its Edge?

    The FDA decided yesterday to expand the use of the ovarian cancer drug Lynparza, sold by AstraZeneca (AZN) and Merck (MRK). The two drugs belong to a class known as PARP inhibitors. Approved in 2014, AstraZeneca's Lynparza was the first such drug to make its way through the FDA.

  • Barrons.com14 hours ago

    Ovarian Cancer Market Still Up For Grabs

    The Food and Drug Administration approved a broader label for AstraZeneca’s (AZN) breast cancer drug Lynparza to be used in ovarian cancer patients. Morgan Stanley’s Andrew Berens and his team are updating their models following the news, writing that he expects the three major players—AstraZeneca, Clovis Oncology (CLVS), and Tesaro (TSRO)—will likely split the market for second line (2L) treatment.

  • See what the IHS Markit Score report has to say about TESARO Inc.
    Markit3 days ago

    See what the IHS Markit Score report has to say about TESARO Inc.

    Short interest is high for TSRO with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TSRO. ETFs that hold TSRO had net inflows of $1.34 billion over the last one-month.